The regulatory landscape for medical devices in the Philippines continues to evolve, reflecting the country’s commitment to strengthening healthcare systems and ensuring patient safety. Recent updates from the Food and Drug Administration of the Philippines highlight a growing focus on compliance, transparency, and alignment with international regulatory standards. These developments are shaping how medical device manufacturers approach market entry and ongoing regulatory obl

Recent regulatory developments in Thailand are drawing the attention of medical device manufacturers and regulatory professionals across Asia. The Thai Food and Drug Administration has announced an extension of the medical device annual reporting deadline, allowing companies additional time to comply with regulatory reporting obligations. The deadline has now been extended to 31 May 2026 , alongside revisions to sales reporting requirements for medical device companies oper

In March 2026, Singapore reached an important milestone in global health regulation. The World Health Organisation (WHO) announced that Singapore’s national regulator, the Health Sciences Authority (HSA), has achieved Maturity Level 4 (ML4) for its medical device regulatory system, the highest classification in WHO’s global benchmarking framework. This recognition positions Singapore as the first country in the world to reach the top regulatory maturity level specifically

Malaysia has taken another step toward modernising its medical device regulatory framework with the release of the 7th Edition of the Guidance Document on Requirements for Labelling of Medical Devices . The update was issued by the Medical Device Authority (MDA), introducing revisions that expand the use of digital labelling and improve accessibility of device information for users. The updated guidance, known as MDA/GD/0026 , provides manufacturers with clearer direction on

Belgium continues to play an important role in the European regulatory landscape for medical devices, with a strong focus on compliance, safety monitoring, and alignment with European regulatory frameworks. The country’s national regulator, the Federal Agency for Medicines and Health Products (FAMHP), oversees the regulation of medicines and medical devices placed on the Belgian market. As the European Union continues to implement the European Union Medical Device Regulation

Switzerland continues to reinforce its regulatory oversight of medical devices as part of its commitment to maintaining high standards for patient safety and product quality. In recent regulatory updates, the Swiss authority has emphasised the importance of robust market surveillance and regulatory compliance for manufacturers placing medical devices on the Swiss market. The country’s regulator, Swissmedic, plays a central role in ensuring that medical technologies available

Post-market surveillance remains a critical pillar of medical device regulation, ensuring that products placed on the market continue to meet safety and performance requirements throughout their lifecycle. In Ireland, the Health Products Regulatory Authority (HPRA) regularly publishes summaries of Field Safety Notices affecting the Irish market, offering valuable insight into ongoing safety monitoring activities. The latest summary covering February 2026 highlights the conti

The United Kingdom is continuing to refine its post-Brexit regulatory framework for medical technologies. In February 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) launched a public consultation exploring the long-term recognition of CE-marked medical devices in Great Britain. The proposal represents an important development in the UK’s evolving medical device regulatory landscape and may significantly influence market access strategies for manufac

China continues to play a central role in the global medical technology market. As innovation in medical devices accelerates, the country’s regulatory framework overseen by the National Medical Products Administration (NMPA) has evolved to ensure that products entering the market meet strict safety, quality, and performance standards. For manufacturers seeking access to the Chinese market, understanding the medical device registration process is essential. The regulatory path

Vietnam is preparing a significant regulatory update for the cosmetics sector. The country’s Ministry of Health has released a draft decree aimed at strengthening oversight of cosmetic products and modernising the existing regulatory framework. If adopted, the new decree would replace current regulations governing cosmetic management and introduce clearer responsibilities for manufacturers, importers, and distributors operating in Vietnam’s rapidly growing beauty and personal

Singapore’s Health Sciences Authority (HSA) has released Revision 4 of its Guidance on Software Medical Devices (GL-04), introducing updated regulatory expectations for Software as a Medical Device (SaMD), including artificial intelligence (AI) and machine learning (ML)-enabled technologies. The revised guidance reflects the rapid growth of digital health solutions and aims to ensure that regulatory oversight keeps pace with emerging software-driven medical technologies. Wit

In January 2026, the U.S. Food and Drug Administration (FDA) finalised its updated Real-World Evidence (RWE) Framework, reinforcing the agency’s commitment to integrating real-world data into regulatory decision-making. The framework strengthens how RWE may be used to support approvals, label expansions, post-market surveillance, and lifecycle management for medical devices and medicinal products. As healthcare systems generate increasing volumes of real-world data, regulator